Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension

NCT00846989 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

276

Enrollment

INDUSTRY

Sponsor class

Conditions

Glaucoma
Ocular Hypertension

Interventions

DRUG: RKI983A
DRUG: RKI983A
DRUG: Latanoprost

Sponsor

Novartis Pharmaceuticals